SAPHNELO: Anifrolumab for Systemic Lupus Erythematosus- Indication, Side Effects and Mechanism of Action
Anifrolumab is the FDA approved antibody therapy for Systemic Lupus Erythematosus Anifrolumab-fnia is a type I interferon (IFN) receptor antagonist, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced in mouse myeloma cells (NS0) by recombinant DNA technology. The molecular weight is approximately 148 kDa. Indication of SAPHNELO/Anifrolumab: SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. The use of SAPHNELO is not recommended in these situations. Contraindications SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia Warning and Precautions Serious Infections: Serious and sometimes fatal infections have occu...